1. Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect.
- Author
-
Nicolaou KC, Rigol S, Pitsinos EN, Das D, Lu Y, Rout S, Schammel AW, Holte D, Lin B, Gu C, Sarvaiya H, Trinidad J, Barbour N, Valdiosera AM, Sandoval J, Lee C, Aujay M, Fernando H, Dhar A, Karsunky H, Taylor N, Pysz M, and Gavrilyuk J
- Subjects
- Animals, Anthraquinones chemistry, Cell Death drug effects, Cell Line, Tumor, Humans, Immunoconjugates chemistry, Mice, Inbred NOD, Mice, SCID, Tumor Burden drug effects, Mice, Anthraquinones pharmacology, Bystander Effect drug effects, Immunoconjugates pharmacology
- Abstract
Antibody-drug conjugates (ADCs) have emerged as valuable targeted anticancer therapeutics with at least 11 approved therapies and over 80 advancing through clinical trials. Enediyne DNA-damaging payloads represented by the flagship of this family of antitumor agents, N -acetyl calicheamicin [Formula: see text], have a proven success track record. However, they pose a significant synthetic challenge in the development and optimization of linker drugs. We have recently reported a streamlined total synthesis of uncialamycin, another representative of the enediyne class of compounds, with compelling synthetic accessibility. Here we report the synthesis and evaluation of uncialamycin ADCs featuring a variety of cleavable and noncleavable linkers. We have discovered that uncialamycin ADCs display a strong bystander killing effect and are highly selective and cytotoxic in vitro and in vivo., Competing Interests: The authors declare no competing interest.
- Published
- 2021
- Full Text
- View/download PDF